MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances a ...

MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025. Details for the Company’s corporate presentation: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ETLonge ...

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus PlanTORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th annual meeting of the Israeli Society for Extracellular Vesicles Research (“ISEVR”), a conference dedicated to cutting-edge exosome science. Additionally, the Company will seek sh ...

- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel, June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPl ...

LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appointment of Sernova’s Chief Executive Officer Jonathan Rigby as Interim Chair of the board of directors. Mr. Rigby will assume the Chair role, effective immediately, until a new independent director is appointed to s ...

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the peer-reviewed journal Regenerative ...

Core Insights - Candel Therapeutics has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational adenovirus immunotherapy candidate, CAN-2409, aimed at treating newly diagnosed localized prostate cancer in patients with intermediate-to-high risk [1][3] - The RMAT designation was based on positive results from a phase III study that demonstrated the safety and efficacy of CAN-2409 in combination with a prodrug and standard of care radiation therapy [2][6] - Following the announcement, Candel's shares increased by 6.1%, although the stock has seen a year-to-date decline of 31.6%, contrasting with the industry's decline of 4.9% [3][4] Company Developments - The phase III study met its primary endpoint, showing statistically significant improvement in disease-free survival for patients receiving the combination therapy compared to standard of care alone [6] - Treatment with CAN-2409 was well tolerated, with no new safety signals identified, leading the company to plan a Biologics License Application (BLA) submission by the end of 2026 [7] - Candel is also exploring CAN-2409 in mid-stage studies for pancreatic and non-small cell lung cancer indications, in addition to its focus on prostate cancer [8] Market Position - Candel currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook within the biotech sector [9] - Other biotech stocks with a similar ranking include Lexicon Pharmaceuticals, Chemomab Therapeutics, and Amarin, each also carrying a Zacks Rank of 2 [9]

Company Overview - Healios K.K. is Japan's leading clinical stage biotechnology company focused on regenerative medicine using stem cells [3] - The company was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 under the TSE Growth Code 4593 [3] Product Development - Healios is developing a proprietary cell product called invimestrocel (HLCM051), which consists of multipotent adult progenitor cells (MAPCs) derived from the bone marrow of healthy adult donors [3] - The company is advancing invimestrocel for indications including ischemic stroke, acute respiratory distress syndrome (ARDS), and trauma [3] - Healios has confirmed its path to conditional approval in Japan for the use of invimestrocel for ARDS and is preparing to file for approval and commercial launch [3] Upcoming Events - Richard Kincaid, Chief Financial Officer of Healios, will present at the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 2:35 PM Eastern Standard Time [1] - A live and archived webcast of the presentation will be accessible from Jefferies' website, with a replay available for 60 days [2]

Bazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companiesEDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and ...

- In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – Collaboration Updates AbbVie Collaboration In February 2025, following a key development milestone, CollPlant received a $2 million milestone payment from its partner, AbbVie, pursuant to the existing development and commercialization agreement. Under this agreement, CollPlant granted AbbVie a worldwide exclusive license to use its recombinant human collagen (rhCollagen) technology in combination with AbbVie's ...